BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 27-Jun-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on June 30, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.

ORIONPHARM 02-Jun-2021

(cont. of ORIONPHARM): The company also has informed that, in this regard, they have applied to the Government of Bangladesh to extend the contract period for supplying electricity for another 5 (five) years and the renewal of contract of both power plants are under process. (end)

ORIONPHARM 02-Jun-2021

The Company has informed that Orion Power Meghnaghat Limited and Dutch Bangla Power & Associates Limited are the subsidiary Companies of Orion Pharma Limited. The contract between Bangladesh Power Development Board and Orion Power Meghnaghat Limited for supplying electricity to the national grid has expired in May 2021 and Dutch Bangla Power & Associates Limited will be expired in July 2021. (cont.)

ORIONPHARM 05-May-2021

(Continuation news of ORIONPHARM): They also informed that this is just a preliminary proposal as a normal and regular business communication of the Company made to RDIF from their end like other Pharmaceutical Companies of the country. But the success will of course depend on the final decision of RDIF and subsequent approval of Govt. of Bangladesh. (end)

ORIONPHARM 05-May-2021

The Company has informed that they have communicated with The Russian Direct Investment Fund (RDIF) and approached them to transfer technology, required for the production of Covid-19 vaccine at the own production plant of Orion Pharma Limited. They have already informed the same to Directorate General of Drug Administration dated May 02, 2021 and Health Services Division, Ministry of Health and Family Welfare dated May 04, 2021. (cont.)

ORIONPHARM 31-Jan-2021

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.

ORIONPHARM 31-Jan-2021

(Continuation news of ORIONPHARM): Consolidated NAV per share including revaluation surplus was Tk. 77.91 as on December 31, 2020 and Tk. 76.77 as on June 30, 2020. Consolidated NAV per share excluding revaluation surplus was Tk. 69.89 as on December 31, 2020 and Tk. 68.69 as on June 30, 2020. (end).

ORIONPHARM 31-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 1.21 for October-December 2020 as against Tk. 0.97 for October-December 2019; Consolidated EPS was Tk. 2.03 for July-December 2020 as against Tk. 2.14 for July-December 2019. Consolidated NOCFPS was Tk. 2.34 for July-December 2020 as against Tk. 3.11 for July-December 2019. (Cont.)

ORIONPHARM 25-Jan-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2021 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.

ORIONPHARM 17-Dec-2020

Trading of the shares of the Company will resume on 20.12.2020 after record date.

Previous Next page